- Home
- BKYI vs CDT Comparison
BKYI vs CDT Comparison
Compare BKYI & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKYI | CDT |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | BKYI | CDT |
|---|---|---|
| Price | $3.46 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.1K | ★ 2.5M |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,302,984.00 | N/A |
| Revenue This Year | $50.61 | N/A |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.81 | N/A |
| 52 Week Low | $0.46 | $0.37 |
| 52 Week High | $5.54 | $11.00 |
Technical Indicators
Market Signals| Indicator | BKYI | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 34.66 |
| Support Level | $0.60 | $0.49 |
| Resistance Level | $5.54 | $1.22 |
| Average True Range (ATR) | 0.47 | 0.35 |
| MACD | 0.18 | -0.03 |
| Stochastic Oscillator | 59.06 | 4.97 |
Price Performance
Historical ComparisonAbout BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.